Kristeleit, RS;
Lorusso, D;
Oaknin, A;
Safra, T;
Swisher, EM;
Bondarenko, IM;
Huzarski, T;
... Oza, A; + view all
(2017)
988TiP: ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer.
Presented at: 42nd ESMO Congress (ESMO 2017), Madrid, Spain.
Preview |
Text
Kristeleit ESMO 2017 ARIEL4 TiP abstract_10May2017c.pdf - Accepted Version Download (357kB) | Preview |
| Type: | Conference item (Presentation) |
|---|---|
| Title: | 988TiP: ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer |
| Event: | 42nd ESMO Congress (ESMO 2017) |
| Location: | Madrid, Spain |
| Dates: | 8 - 12 September 2017 |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://doi.org/10.1093/annonc/mdx372.059 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1574295 |
Archive Staff Only
 |
View Item |
